Ranbaxy resumes production of generic atorvastatin
Ranbaxy Laboratories has once again started production of atorvastatin for sale in the US after a voluntary recall stopped the process in November. (Source: theHeart.org)
Source: theHeart.org - February 27, 2013 Category: Cardiology Source Type: news

Ranbaxy restarts production of generic Lipitor for US market
"We are working with the USFDA, and have identified and implemented multiple corrective and preventive actions," Ranbaxy said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 25, 2013 Category: Pharmaceuticals Source Type: news

Production of Generic Lipitor Resumes
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 24, 2013 Category: Primary Care Tags: Medical News Source Type: news

Statin Drug Production Resumes at Ranbaxy
Ranbaxy, which had more than 40 percent of the United States market for generic Lipitor in October, said it had been working with the F.D.A. to solve quality problems in making the drug. (Source: NYT Health)
Source: NYT Health - February 23, 2013 Category: Consumer Health News Authors: By KATIE THOMAS Tags: India Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Food and Drug Administration Ranbaxy Laboratories Lipitor (Drug) Food Contamination and Poisoning Source Type: news

Ranbaxy to resume generic Lipitor production for U.S
(Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Friday it will resume production of its version of Pfizer's cholesterol fighter Lipitor for sale in the United States after resolving the issues that led to a November recall. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

RCCT of Atorvastatin in Reducing the Severity of SepsisRCCT of Atorvastatin in Reducing the Severity of Sepsis
Do statin naive patients with sepsis have lower severity of illness with a daily dose of atorvastatin? Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2013 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

Initiating Atorvastatin in Severe Sepsis Isn't Helpful: StudyInitiating Atorvastatin in Severe Sepsis Isn't Helpful: Study
Starting atorvastatin in critically ill patients with severe sepsis did not reduce inflammation or improve survival in a phase II study from the ANZICS Clinical Trials Group. Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 8, 2013 Category: Intensive Care Tags: Critical Care News Source Type: news

Are Drugs for Ultra-Rare Diseases the Future of Biotech? Francois Nader of NPS Weighs In
Over the last ten years, the global pharmaceutical industry has undergone dramatic changes. In the 1990s, big drug companies made hundreds of billions of dollars selling slightly improved versions of their competitors’ drugs; think of the epic battle between cholesterol-lowering drugs Lipitor and Zocor. Since then, however, an entirely new business model has emerged: developing drugs for rare, or “orphan” diseases, which are far easier to get through the FDA, and for which companies can charge significantly higher prices. The latest entry into the field is NPS Pharmaceuticals’ Gattex, which was approved last Decemb...
Source: Forbes.com Healthcare News - February 5, 2013 Category: Pharmaceuticals Authors: Avik Roy Source Type: news

Medicines Co. Licenses Rights to Cholesterol Drug
The drug inhibits the protein PCSK9 and might one day be used to treat millions of people whose cholesterol is not lowered enough by common statins, such as Lipitor. (Source: NYT Health)
Source: NYT Health - February 4, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Biogen Idec Inc BIIB NASDAQ Cambridge (Mass) Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Roche Holding A G RHHBY Other OTC Sanofi SA SNY NYSE Cholesterol Amgen Inc AMGN NASDAQ Alnylam Pharmaceuticals Inc ALNY NASDAQ Regeneron Pharmaceuti Source Type: news

Outsource Or Manage Internally? Pharma Logistics, 9-10 April 2013, Vienna, Austria
"The current trend in pharma logistics is the shift from blockbuster drugs. 6 out of 10 top selling drugs will lose their patents in one year, so there will be increase in the use of generic drugs," Sebastiaan Scholte, Chairman at Cool Chain Association, pointed out when speaking about the latest developments. These trends influence drug manufacturers and make them rethink their strategies. Already without medications like Lipitor and Plavix bolstering their bottom lines, manufacturers have to cut costs in order to stay competitive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 31, 2013 Category: Consumer Health News Tags: Conferences Source Type: news

Pfizer hints core drugs unit may be split
The chief’s comments come as it reports a jump in fourth-quarter profits, as proceeds from the sale of its nutrition business offsets lost Lipitor sales (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 29, 2013 Category: Pharmaceuticals Source Type: news

Merck Resubmits Data to FDA for Ezetimibe/Atorvastatin ComboMerck Resubmits Data to FDA for Ezetimibe/Atorvastatin Combo
The resubmission of the updated new drug application includes the additional data requested by the FDA, and the company expects the FDA review to be completed in the first half of 2013. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Merck resubmits data to FDA for ezetimibe/atorvastatin combo, again
The resubmission of the updated new drug application includes the additional data requested by the FDA, and the company expects the FDA review to be completed in the first half of 2013. (Source: theHeart.org)
Source: theHeart.org - January 8, 2013 Category: Cardiology Source Type: news

The debate for generics: a view on statin therapy
Source: JAMA Internal Medicine Area: News Related to the results of a survey of US Physicians in which researchers sought to determine how frequently physicians comply with requests for brand-name drugs or the factors predicting this behaviour, JAMA Internal Medicine has featured a review of the case for generics when considering statin therapy.   The review considers the following: . Comparing statin efficacy . The choice of generic statins   The authors conclude that "lowering LDL-C level does not always reduce cardiovascular risk, although risk reduction is the appropriate goal of the...
Source: NeLM - Cardiovascular Medicine - January 8, 2013 Category: Cardiology Source Type: news

Merck's Combination Of Ezetimibe And Atorvastatin Back On NDA Path
A combination tablet containing the cholesterol-lowering drugs ezetimibe and atorvastatin is back on the path to possible FDA approval, according to Merck, which already markets Zetia (ezetimibe) and Vytorin, the combination of ezetimibe and simvastatin. Merck has repeatedly stumbled in its efforts to gain FDA approval of the proposed new drug, which has been dubbed "Son of Vytorin." The new drug application (NDA) submission was first rejected by the FDA in 2009 and, again, last year. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 3, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news